Our vision
We are a Medical company that aims to build innovant tools to personnalize medical care to the closest needs of the patient… With two major objectives: Improve life quality and lifetime of everyone !
During the Sars-CoV-2 pandemic
The Sars-CoV-2 pandemic revealed the lack of tools for early identification of lung lesions during virus-induce acute respiratory failure.
Early recognition of high-risk patient would be of major medical benefit by giving patient the best therapy at the best time.
Disturbed by the lack of biomarkers, we sought to help clinicians by identifying early organ damage with a simple liquid biopsy (blood/urine) sample, based on a molecular technology platform.
At CGenetix, we believe in starting small and then gradually becoming big… For this reason, we wanted to focus our development on the follow-up of kidney transplant patients.
Epidemiology
Europe
21 000 new kidney transplants performed each year and 200 000 patients living with a transplanted kidney
USA
22 000 new kidney transplanted performed each year and 230 000 patients living with a transplanted kidney
Epidemiology
Europe
21 000 new kidney transplants performed each year and 200 000 patients living with a transplanted kidney
USA
22 000 new kidney transplanted performed each year and 230 000 patients living with a transplanted kidney
Development plan
We already patented brain, kidney & lung biomarkers and an analytical methodology to analyze these biomarkers in different clinical applications. Scientific publication are on going
Who are behind all of this ?
We are a complementary team with cross-functional skills, particularly in -omics data analysis, molecular biology and clinical data analysis.
Our scientific partners
Our project is already supported by various academic and hospital partners making possible to achieve our objectives of tomorrow.